Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11%…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
January 19, 2026 03:00 ET | Source: Concept Life Sciences CHAPEL-EN-LE-FRITH, United Kingdom, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Concept…
LONDON and BARCELONA, Spain, Jan. 19, 2026 (GLOBE NEWSWIRE) -- SEON, the command center for real-time fraud prevention and AML…
Almere, The NetherlandsJanuary 19, 2026, 8:00 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today announces, based on preliminary figures,…
January 19, 2026 02:00 ET | Source: RIBER Riber receives a new order from Japan for MBE 6000 to scale…
January 16, 2026 16:05 ET | Source: Context Therapeutics Inc. PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.…
January 16, 2026 16:05 ET | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”…
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…
NEURODYNE DROPS INTRODUCED AS A COGNITIVE WELLNESS SUPPLEMENT SUPPORTING HEALTHY MEMORY, FOCUS, AND MENTAL CLARITY New York City, NY, Jan.…